823 CD4 T cells are essential for an anti-tumor effect in a B78 murine melanoma tumor model. (9th November 2020)
- Record Type:
- Journal Article
- Title:
- 823 CD4 T cells are essential for an anti-tumor effect in a B78 murine melanoma tumor model. (9th November 2020)
- Main Title:
- 823 CD4 T cells are essential for an anti-tumor effect in a B78 murine melanoma tumor model
- Authors:
- Feils, Arika
Heck, Mackenzie
Hoefges, Anna
Carlson, Peter
Zangl, Luke
Patel, Ravi
Kravtsov, Dmitriy
Hank, Jacquelyn
Morris, Zachary
Rakhmilevich, Alexander
Sondel, Paul
Erbe, Amy - Abstract:
- Abstract : Background: Mice bearing B78 melanoma tumors can be cured using an in situ vaccine (ISV) regimen that includes radiation (RT) together with immunocytokine (tumor-targeting mAb conjugated to IL-2). B78 melanoma cells, derived from B16 cells, express minimal to no MHC-I but express MHC-II upon IFN-g/TNF-a stimulation. Although B78 cells are primarily MHC-I-deficient, an increased CD8 T cell infiltration into the tumor microenvironment (TME) has been shown following ISV. 1 To further investigate the potential role of specific immune cell lineages in the B78 anti-tumor response to ISV, immune subset depletion studies and flow cytometric analyses were performed. Methods: C57BL/6 mice bearing B78 tumors were depleted of immune cell subsets with mAbs (anti-CD4, anti-CD8, anti-NK1.1, or Rat IgG control) for 3 weeks during the course of treatment. Treatment groups included no treatment, RT (12 Gy), or ISV (RT D0 and immunocytokine D5-D9). 6 mice/group (repeated three times) were followed for survival/tumor growth, and flow cytometry studies included 4 mice/group, sacrificed on D8 and D13 following the start of ISV. Results: Mice depleted of CD4 T cells during the course of ISV showed a significant reduction of anti-tumor effect as compared to mice treated with ISV/Rat IgG (p Conclusions: These studies suggest that CD4 T cells are essential for an anti-tumor response in the B78 melanoma model. In vivo depletion data show that CD4 T cells, but not CD8 or NK cells, areAbstract : Background: Mice bearing B78 melanoma tumors can be cured using an in situ vaccine (ISV) regimen that includes radiation (RT) together with immunocytokine (tumor-targeting mAb conjugated to IL-2). B78 melanoma cells, derived from B16 cells, express minimal to no MHC-I but express MHC-II upon IFN-g/TNF-a stimulation. Although B78 cells are primarily MHC-I-deficient, an increased CD8 T cell infiltration into the tumor microenvironment (TME) has been shown following ISV. 1 To further investigate the potential role of specific immune cell lineages in the B78 anti-tumor response to ISV, immune subset depletion studies and flow cytometric analyses were performed. Methods: C57BL/6 mice bearing B78 tumors were depleted of immune cell subsets with mAbs (anti-CD4, anti-CD8, anti-NK1.1, or Rat IgG control) for 3 weeks during the course of treatment. Treatment groups included no treatment, RT (12 Gy), or ISV (RT D0 and immunocytokine D5-D9). 6 mice/group (repeated three times) were followed for survival/tumor growth, and flow cytometry studies included 4 mice/group, sacrificed on D8 and D13 following the start of ISV. Results: Mice depleted of CD4 T cells during the course of ISV showed a significant reduction of anti-tumor effect as compared to mice treated with ISV/Rat IgG (p Conclusions: These studies suggest that CD4 T cells are essential for an anti-tumor response in the B78 melanoma model. In vivo depletion data show that CD4 T cells, but not CD8 or NK cells, are required for a decrease in tumor growth via ISV. Flow cytometric analyses suggest an interplay between CD4 and CD8 T cells as indicated by a decrease in CD8/IFN-g expression following ISV in the absence of CD4 T cells. The role that MHC-I and MHC-II expression plays in this CD4/CD8 T cell anti-tumor response is under investigation. In future studies, B78 melanoma may serve as a critical syngeneic model for development of more effective immunotherapy treatment regimens. Ethics Approval: All animal experiments were performed in accordance with protocols approved by Animal Care and Use Committees of the University of Wisconsin-Madison. Reference: Morris Z, Guy E, Francis D, et al. In situ tumor vaccination by combining local radiation and tumor-specific antibody or immunocytokine treatments. Cancer Res 2016;76(13):3929-3941. … (more)
- Is Part Of:
- Journal for immunotherapy of cancer. Volume 8(2020)Supplement 3
- Journal:
- Journal for immunotherapy of cancer
- Issue:
- Volume 8(2020)Supplement 3
- Issue Display:
- Volume 8, Issue 3 (2020)
- Year:
- 2020
- Volume:
- 8
- Issue:
- 3
- Issue Sort Value:
- 2020-0008-0003-0000
- Page Start:
- A873
- Page End:
- A873
- Publication Date:
- 2020-11-09
- Subjects:
- Cancer -- Immunotherapy -- Periodicals
Cancer -- Immunological aspects -- Periodicals
Tumors -- Immunological aspects -- Periodicals
Immunotherapy -- Periodicals
616.99406105 - Journal URLs:
- http://www.immunotherapyofcancer.org ↗
https://jitc.bmj.com/ ↗
http://link.springer.com/ ↗ - DOI:
- 10.1136/jitc-2020-SITC2020.0823 ↗
- Languages:
- English
- ISSNs:
- 2051-1426
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 19732.xml